Highly potent, selective, ATP-competitive, and orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with an IC50 value of 9.9 nM. Moreover, XL 388 is an mTORC1/2 dual inhibitor which displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. XL 388 showed anti-cancer activity in preclinical osteosarcoma models and inhibited survival and proliferation of RCC cell lines and primary human RCC cells.

KEYWORDS: XL 388 | supplier | mTOR inhibitor | XL388 | XL-388 | CAS [1251156-08-7] | [1777807-51-8] | Phosphatidylinositol | mTOR | Inhibitor | Enzymes | Osteosarcoma | RCC